Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Ramucirumab With or Without Cemiplimab in Stage IV or Recurrent NSCLC
NCT06616584Phase 3Recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cemiplimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by SWOG Cancer Research Network. Primary endpoint: Overall Survival up to 3 years. Started May 2025; status: recruiting.
02
Drugs
cemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06616584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06616584.